1. Home
  2. MDT vs VRTX Comparison

MDT vs VRTX Comparison

Compare MDT & VRTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MDT
  • VRTX
  • Stock Information
  • Founded
  • MDT 1949
  • VRTX 1989
  • Country
  • MDT Ireland
  • VRTX United States
  • Employees
  • MDT N/A
  • VRTX N/A
  • Industry
  • MDT Biotechnology: Electromedical & Electrotherapeutic Apparatus
  • VRTX EDP Services
  • Sector
  • MDT Health Care
  • VRTX Technology
  • Exchange
  • MDT Nasdaq
  • VRTX Nasdaq
  • Market Cap
  • MDT 119.3B
  • VRTX 104.8B
  • IPO Year
  • MDT N/A
  • VRTX 1991
  • Fundamental
  • Price
  • MDT $89.86
  • VRTX $484.82
  • Analyst Decision
  • MDT Hold
  • VRTX Buy
  • Analyst Count
  • MDT 15
  • VRTX 25
  • Target Price
  • MDT $94.64
  • VRTX $507.57
  • AVG Volume (30 Days)
  • MDT 8.0M
  • VRTX 1.3M
  • Earning Date
  • MDT 05-22-2025
  • VRTX 05-05-2025
  • Dividend Yield
  • MDT 3.12%
  • VRTX N/A
  • EPS Growth
  • MDT 3.82
  • VRTX N/A
  • EPS
  • MDT 3.27
  • VRTX N/A
  • Revenue
  • MDT $33,199,000,000.00
  • VRTX $11,020,100,000.00
  • Revenue This Year
  • MDT $4.52
  • VRTX $10.65
  • Revenue Next Year
  • MDT $4.44
  • VRTX $9.02
  • P/E Ratio
  • MDT $27.48
  • VRTX N/A
  • Revenue Growth
  • MDT 2.72
  • VRTX 11.66
  • 52 Week Low
  • MDT $75.96
  • VRTX $377.85
  • 52 Week High
  • MDT $96.25
  • VRTX $519.88
  • Technical
  • Relative Strength Index (RSI)
  • MDT 47.28
  • VRTX 44.83
  • Support Level
  • MDT $87.52
  • VRTX $497.78
  • Resistance Level
  • MDT $89.45
  • VRTX $513.98
  • Average True Range (ATR)
  • MDT 1.69
  • VRTX 12.52
  • MACD
  • MDT -0.51
  • VRTX -3.56
  • Stochastic Oscillator
  • MDT 43.15
  • VRTX 27.65

About MDT Medtronic plc.

One of the largest medical-device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, heart valves, stents, insulin pumps, spinal fixation devices, neurovascular products, advanced energy, and surgical tools. The company markets its products to healthcare institutions and physicians in the United States and overseas. Foreign sales account for roughly 50% of the company's total sales.

About VRTX Vertex Pharmaceuticals Incorporated

Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease. Additionally, Vertex is evaluating small-molecule inhibitors targeting acute and chronic pain using nonopioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.

Share on Social Networks: